Joint Session on the Relationship Between Impurities and Immunogenicity

Moderator(s)

• 

  Lynn Kamen, PhD

  Scientific Officer, Executive Director
  BioAgilytix
  Durham, North Carolina

Presentations:

• 8:05 AM - 8:35 AM ET

  Framework towards control of immunogenicity risks for impurities and contaminants
  

  Speaker: Timothy P. Hickling, PhD – Roche
• 8:35 AM - 9:05 AM ET

  Tiered, Data-driven Approach for Assessing the Safety of Peptide-Related Impurities
  

  Speaker: Robert Siegel, PhD (he/him/his) – Eli Lilly and Company
• 9:05 AM - 9:35 AM ET

  Case Studies Assessing Immunogenicity Risk of Recombinant Therapeutic Protein Attributes with Implications for Parenteral Drug Product Manufacturing
  

  Speaker: Joseph R. Cohen, PhD (he/him/his) – Amgen Inc.
• 9:35 AM - 10:30 AM ET

  Joint Session on the Relationship Between Impurities and Immunogenicity: Panel Discussion
  

  Moderator: Lynn Kamen, PhD – BioAgilytix

  Speaker: Timothy P. Hickling, PhD – Roche

  Speaker: Robert Siegel, PhD (he/him/his) – Eli Lilly and Company

  Speaker: Joseph R. Cohen, PhD (he/him/his) – Amgen Inc.
• 10:30 AM - 10:35 AM ET

  Closing Remarks: 2026 SSF Program Chair
  

  Moderator: Landon Greene, PhD (he/him/his) – Vertex Pharmaceuticals